Affinity Asset Advisors »

Beigene shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Beigene (BGNE) shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Beigene

Tip: Access up to 7 years of quarterly data

All positions including Beigene held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Beigene by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2024-06-30 $16M 110k 142.67
2024-03-31 $13M 82k 156.39

More positions owned by Affinity Asset Advisors

Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Xenon Pharmaceuticals (XENE)
Apogee Therapeutics (APGE)
Madrigal Pharmaceuticals (MDGL)
Cerevel Therapeutics Hldng I (CERE)
Arcellx Common Stock (ACLX)
Crinetics Pharmaceuticals In (CRNX)
Nurix Therapeutics (NRIX)
Celldex Therapeutics Com New (CLDX)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Alnylam Pharmaceuticals Note 1.000% 9/1 (Principal)
Beigene Sponsored Adr (BGNE)
Alkermes SHS (ALKS)
Nuvalent Inc-a (NUVL)

View all positions for Affinity Asset Advisors

Top funds holding Beigene

Baker Bros. Advisors
Capital Research and Management Company - Division 3
Hillhouse Capital Advisors
PRIMECAP Management Company
Baillie Gifford & Co
Temasek Holdings
T. Rowe Price Associates
FMR
BlackRock
Capital International
Boxer Capital
Point72 Asset Management
Public Investment Fund
Vestal Point Capital
Artal Group

View all funds holding Beigene